<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Ezatiostat, a <z:chebi fb="0" ids="16856">glutathione</z:chebi> S-transferase P1-1 inhibitor, promotes the maturation of hematopoietic progenitors and induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>RESULTS: Ezatiostat was administered to 19 patients with non-deletion(5q) <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) at one of two doses (2000 mg or 2500 mg/day) in combination with 10 mg of lenalidomide on days 1-21 of a 28-day cycle </plain></SENT>
<SENT sid="2" pm="."><plain>No unexpected toxicities occurred and the incidence and severity of adverse events (AEs) were consistent with that expected for each drug alone </plain></SENT>
<SENT sid="3" pm="."><plain>The most common non-hematologic AEs related to ezatiostat in combination with lenalidomide were mostly grade 1 and 2 <z:mp ids='MP_0002899'>fatigue</z:mp>, <z:hpo ids='HP_0002039'>anorexia</z:hpo>, <z:hpo ids='HP_0002018'>nausea</z:hpo>, <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, and <z:hpo ids='HP_0002013'>vomiting</z:hpo>; hematologic AEs due to lenalidomide were <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, and <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>One of 4 evaluable patients (25%) in the 2500/10 mg dose group experienced an erythroid hematologic improvement (HI-E) response by 2006 MDS International Working Group (IWG) criteria </plain></SENT>
<SENT sid="5" pm="."><plain>Four of 10 evaluable patients (40%) in the 2000 mg/10 mg dose group experienced an HI-E response </plain></SENT>
<SENT sid="6" pm="."><plain>Three of 7 (43%) red blood cell (RBC) transfusion-dependent patients became RBC transfusion independent, including one patient for whom prior lenalidomide monotherapy was ineffective </plain></SENT>
<SENT sid="7" pm="."><plain>Three of 5 (60%) thrombocytopenic patients had an HI-platelet (HI-P) response </plain></SENT>
<SENT sid="8" pm="."><plain>Bilineage HI-E and HI-P responses occurred in 3 of 5 (60%), 1 of 3 with HI-E and HI-N (33%), and 1 of 3 with HI-N and HI-P (33%) </plain></SENT>
<SENT sid="9" pm="."><plain>One of 3 patients (33%) with <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> experienced a complete trilineage response </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> multilineage responses were observed in the 2000/10 mg doses recommended for future studies </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: The tolerability and activity profile of ezatiostat co-administered with lenalidomide supports the further development of ezatiostat in combination with lenalidomide in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and also encourages studies of this combination in other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> where lenalidomide is active </plain></SENT>
</text></document>